Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Erlotinib Action Pathway
Homo sapiens
Drug Action Pathway
Erlotinib is an anti-EGFR drug used in the treatment of some cancers. EGFR is linked multiple signalling pathways involved in tumour growth and angiogenesis such as the Ras/Raf pathway and the PI3K/Akt pathways. These pathways ultimately lead to the activation of transcription factors such as Jun, Fos, and Myc, as well as cyclin D1, which stimulates cell growth and mitosis. Uncontrolled cell growth and mitosis leads to cancer. Erlotinib acts as an anticancer drug by binding to the intracellular tyrosine kinase domain of the EGFR and blocking its activity. This in turn inhibits downstream signalling and prevents tumour growth.
References
Erlotinib Pathway References
Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010 Mar;29(1):37-48. doi: 10.1007/s10555-010-9201-z.
Pubmed: 20127143
Lurje G, Lenz HJ: EGFR signaling and drug discovery. Oncology. 2009;77(6):400-10. doi: 10.1159/000279388. Epub 2010 Feb 2.
Pubmed: 20130423
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings